Please Wait.....
Report
Primary Sclerosing Cholangitis - Epidemiology Forecast - 2032
Market Report I 2022-08-01 I 91 Pages I DelveInsight
DelveInsight's 'Primary Sclerosing Cholangitis (PSC) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of Primary Sclerosing Cholangitis (PSC) historical and forecasted epidemiology in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.
Primary Sclerosing Cholangitis (PSC) Disease Understanding
Primary sclerosing cholangitis (PSC) is a chronic disease that slowly damages the bile ducts. In PSC patients, the bile ducts are blocked due to inflammation and scarring or fibrosis, leading to the accumulation of bile in the liver, which gradually damages liver cells and causes cirrhosis or fibrosis of the liver. As cirrhosis progresses and the amount of scar tissue in the liver increases, the liver slowly loses its functionality. The scar tissue may block the drainage of the bile ducts leading to bile infection.
Primary Sclerosing Cholangitis (PSC) Epidemiology
The Primary Sclerosing Cholangitis (PSC) epidemiology division provides insights into the historical and prevalent patient pool, along with the forecasted trend for all the seven major countries + Nordic countries. It recognizes the causes of current and forecasted trends by exploring numerous studies and views of KOL. The report also provides the diagnosed patient pool, trends, and assumptions.
Key Findings
The total diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC) patients in the 7MM + Nordic countries are increasing during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted Primary Sclerosing Cholangitis (PSC) epidemiology segmented as the total diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC), gender-specific cases of Primary Sclerosing Cholangitis (PSC), comorbidity-specific cases of Primary Sclerosing Cholangitis (PSC), symptom-specific cases of Primary Sclerosing Cholangitis (PSC). The report includes the diagnosed prevalent cases scenario of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan from 2019 to 2032.
Country-wise Primary Sclerosing Cholangitis (PSC) Epidemiology
The epidemiology segment also provides the Primary Sclerosing Cholangitis (PSC) epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan.
The diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC) associated in the 7MM + Nordic countries were approximately 59,000 in 2021.
- As per the estimates, the United States has the largest diagnosed prevalent population of Primary Sclerosing Cholangitis (PSC)
- Among the EU-5 countries, Germany had the highest diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC), followed by France. On the other hand, Spain had the lowest diagnosed prevalent cases, with around 100 cases in 2021
- Sweden had the highest diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC) among Nordic countries, followed by Finland. On the other hand, Norway had the lowest diagnosed prevalent cases, with around 900 cases in 2021
Scope of the Report
- The Primary Sclerosing Cholangitis (PSC) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
- The Primary Sclerosing Cholangitis (PSC) epidemiology report and model provide an overview of Primary Sclerosing Cholangitis (PSC)' risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) + Nordic countries (Sweden, Finland, Denmark, and Norway)
- The report provides insight into Primary Sclerosing Cholangitis (PSC)' historical and forecasted patient pool in the seven major markets along with Nordic countries covering the United States, the EU-5 (Germany, Spain, France, Italy, UK), Nordic countries (Sweden, Finland, Denmark, and Norway), and Japan
- The report helps to recognize the growth opportunities in the 7MM + Nordic countries concerning the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Primary Sclerosing Cholangitis (PSC)
- The report provides the segmentation of the Primary Sclerosing Cholangitis (PSC) epidemiology by the diagnosed prevalent cases of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries
- The report provides the Primary Sclerosing Cholangitis (PSC) epidemiology segmentation by gender-specific cases of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries
- The report provides the Primary Sclerosing Cholangitis (PSC) epidemiology segmentation by comorbidity-specific cases of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries
- The report provides the Primary Sclerosing Cholangitis (PSC) epidemiology segmentation by symptom-specific cases of Primary Sclerosing Cholangitis (PSC) in the 7MM + Nordic countries
Report Highlights
- 11-year Forecast of Primary Sclerosing Cholangitis (PSC) Epidemiology
- 7MM + Nordic countries Coverage
- Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC)
- Gender-specific cases of Primary Sclerosing Cholangitis (PSC)
- Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC)
- Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC)
KOL Views
We interview KOLs, and SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.
Key Questions Answered
- What are the major factors that will drive the change in the patient population in Primary Sclerosing Cholangitis (PSC) during the forecast period (2019-2032)?
- What are the key findings of the Primary Sclerosing Cholangitis (PSC) epidemiology across the 7MM + Nordic countries, and which country will have the highest number of patients during the forecast period (2019-2032)?
- What would be the total number of Primary Sclerosing Cholangitis (PSC) patients across the 7MM + Nordic countries during the forecast period (2019-2032)?
- Among the EU-5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in the 7MM + Nordic countries during the forecast period (2019-2032)?
- What are the disease risks, burdens, and unmet needs of the Primary Sclerosing Cholangitis (PSC) market?
- What are the current treatment patterns for Primary Sclerosing Cholangitis (PSC)?
Reasons to Buy
The Primary Sclerosing Cholangitis (PSC) epidemiology report will allow the user to
- Develop business strategies by understanding the trends shaping and driving the global Primary Sclerosing Cholangitis (PSC) market
- Quantify patient populations in the global Primary Sclerosing Cholangitis (PSC) market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Primary Sclerosing Cholangitis (PSC) therapeutics in each market covered
- Understand the magnitude of the Primary Sclerosing Cholangitis (PSC) population by its diagnosed prevalence
- Understand the magnitude of the Primary Sclerosing Cholangitis (PSC) population by its Gender-specific cases
- Understand the magnitude of the Primary Sclerosing Cholangitis (PSC) population by its Comorbidity-specific cases
- Understand the magnitude of the Primary Sclerosing Cholangitis (PSC) population by its Symptom-specific cases
- The Primary Sclerosing Cholangitis (PSC) epidemiology report and model were written and developed by Master and PhD level epidemiologists
- The Primary Sclerosing Cholangitis (PSC) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Key Assessments
- Patient segmentation
- Disease risk and burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Nordic countries (Sweden, Finland, Denmark, and Norway)
- Japan
Study Period: 2019-2032
1. Key Insights
2. Report Introduction
3. Primary Sclerosing Cholangitis (PSC) Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Primary Sclerosing Cholangitis (PSC) in 2019
3.2. Patient Share (%) Distribution of Primary Sclerosing Cholangitis (PSC) in 2032
4. Executive Summary of Primary Sclerosing Cholangitis (PSC)
5. Disease Background and Overview
5.1. Introduction
5.2. Classification of Sclerosing Cholangitis
5.3. Clinical Phenotypes
5.4. Clinical Manifestations
5.5. Etiology and Risk Factors
5.6. Pathogenesis
5.7. Malignant Diseases Associated With PSC
5.8. Complications Associated With PSC
5.9. Diagnosis
5.10. Treatment
5.11. Clinical Practice Guidelines
5.11.1. Diagnostic Guidelines
5.11.1.1. American College of Gastroenterology (ACG) Guidelines
5.11.1.2. American Association for the Study of Liver Diseases (AASLD)
5.11.1.3. British Society of Gastroenterology and UK-PSC Guidelines for PSC diagnosis
5.11.2. Treatment Guidelines
5.11.2.1. American Association for the Study of Liver Diseases (AASLD)
5.11.2.2. American College of Gastroenterology (ACG) Guidelines
5.11.2.3. British Society of Gastroenterology and UK-PSC guidelines for the management of PSC
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM + Nordic Countries Total Diagnosed Prevalent Population of Primary Sclerosing Cholangitis
6.3. The United States
6.3.1. Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the United States
6.3.2. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States
6.3.3. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States
6.3.4. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States
6.4. The EU-5
6.4.1. Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the EU-5
6.4.2. Germany
6.4.2.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany
6.4.2.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany
6.4.2.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany
6.4.3. France
6.4.3.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in France
6.4.3.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in France
6.4.3.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in France
6.4.4. Italy
6.4.4.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy
6.4.4.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy
6.4.4.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy
6.4.5. Spain
6.4.5.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain
6.4.5.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain
6.4.5.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain
6.4.6. The United Kingdom
6.4.6.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom
6.4.6.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom
6.4.6.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom
6.5. Nordic Countries
6.5.1. Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Nordic Countries
6.5.2. Sweden
6.5.2.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden
6.5.2.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden
6.5.2.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden
6.5.3. Finland
6.5.3.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland
6.5.3.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland
6.5.3.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland
6.5.4. Denmark
6.5.4.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark
6.5.4.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark
6.5.4.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark
6.5.5. Norway
6.5.5.1. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway
6.5.5.2. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway
6.5.5.3. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway
6.6. Japan
6.6.1. Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Japan
6.6.2. Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan
6.6.3. Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan
6.6.4. Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan
7. Patient Journey
8. KOL Views
9. Acronyms and Abbreviations
10. Appendix
10.1. Bibliography
10.2. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
Table 1: Summary of Primary Sclerosing Cholangitis (PSC), Epidemiology, and Key Events (2019-2032)
Table 2: Phenotypic Variants of PSC
Table 3: 7MM + Nordic Countries Total Diagnosed Prevalent Population of Primary Sclerosing Cholangitis (PSC) (2019-2032)
Table 4: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019-2032)
Table 5: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019-2032)
Table 6: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019-2032)
Table 7: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019-2032)
Table 8: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the EU-5 (2019-2032)
Table 9: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019-2032)
Table 10: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019-2032)
Table 11: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019-2032)
Table 12: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019-2032)
Table 13: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019-2032)
Table 14: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019-2032)
Table 15: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019-2032)
Table 16: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019-2032)
Table 17: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019-2032)
Table 18: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019-2032)
Table 19: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019-2032)
Table 20: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019-2032)
Table 21: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019-2032)
Table 22: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019-2032)
Table 23: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019-2032)
Table 24: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Nordic Countries (2019-2032)
Table 25: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019-2032)
Table 26: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019-2032)
Table 27: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019-2032)
Table 28: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019-2032)
Table 29: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019-2032)
Table 30: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019-2032)
Table 31: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019-2032)
Table 32: Comorbidities-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019-2032)
Table 33: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019-2032)
Table 34: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019-2032)
Table 35: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019-2032)
Table 36: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019-2032)
Table 37: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019-2032)
Table 38: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019-2032)
Table 39: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019-2032)
Table 40: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019-2032)
Figure 1: Types of Sclerosing Cholangitis
Figure 2: Risk Factors Involved in PSC
Figure 3: Pathogenesis of PSC
Figure 4: Diagnostic Algorithm
Figure 5: Algorithmic Approach to the Management of PSC and its Complications
Figure 6: 7MM + Nordic Countries Total Diagnosed Prevalent Population of Primary Sclerosing Cholangitis (PSC) (2019-2032)
Figure 7: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019-2032)
Figure 8: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019-2032)
Figure 9: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019-2032)
Figure 10: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United States (2019-2032)
Figure 11: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in the EU-5 (2019-2032)
Figure 12: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019-2032)
Figure 13: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019-2032)
Figure 14: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Germany (2019-2032)
Figure 15: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019-2032)
Figure 16: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019-2032)
Figure 17: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in France (2019-2032)
Figure 18: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019-2032)
Figure 19: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019-2032)
Figure 20: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Italy (2019-2032)
Figure 21: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019-2032)
Figure 22: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019-2032)
Figure 23: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Spain (2019-2032)
Figure 24: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019-2032)
Figure 25: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019-2032)
Figure 26: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in the United Kingdom (2019-2032)
Figure 27: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Nordic Countries (2019-2032)
Figure 28: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019-2032)
Figure 29: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019-2032)
Figure 30: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Sweden (2019-2032)
Figure 31: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019-2032)
Figure 32: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019-2032)
Figure 33: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Finland (2019-2032)
Figure 34: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019-2032)
Figure 35: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019-2032)
Figure 36: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Denmark (2019-2032)
Figure 37: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019-2032)
Figure 38: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019-2032)
Figure 39: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Norway (2019-2032)
Figure 40: Total Diagnosed Prevalent Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019-2032)
Figure 41: Gender-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019-2032)
Figure 42: Comorbidity-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019-2032)
Figure 43: Symptom-specific Cases of Primary Sclerosing Cholangitis (PSC) in Japan (2019-2032)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security